Mirae Asset Global Investments Co. Ltd. Purchases New Holdings in IDEXX Laboratories, Inc. $IDXX

Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 58,225 shares of the company’s stock, valued at approximately $30,405,000. Mirae Asset Global Investments Co. Ltd. owned approximately 0.07% of IDEXX Laboratories at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Arlington Trust Co LLC lifted its position in shares of IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after acquiring an additional 19 shares during the period. Annis Gardner Whiting Capital Advisors LLC grew its holdings in shares of IDEXX Laboratories by 21.4% during the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company’s stock worth $67,000 after purchasing an additional 21 shares in the last quarter. Arlington Capital Management Inc. increased its position in shares of IDEXX Laboratories by 4.8% in the first quarter. Arlington Capital Management Inc. now owns 479 shares of the company’s stock worth $269,000 after purchasing an additional 22 shares during the period. Valeo Financial Advisors LLC increased its position in shares of IDEXX Laboratories by 6.4% in the second quarter. Valeo Financial Advisors LLC now owns 383 shares of the company’s stock worth $202,000 after purchasing an additional 23 shares during the period. Finally, Carnegie Investment Counsel increased its position in shares of IDEXX Laboratories by 1.3% in the first quarter. Carnegie Investment Counsel now owns 2,000 shares of the company’s stock worth $1,124,000 after purchasing an additional 25 shares during the period. Institutional investors own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.79% of the company’s stock.

IDEXX Laboratories Trading Up 21.8%

Shares of IDXX opened at $671.64 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98. The firm has a market cap of $52.91 billion, a price-to-earnings ratio of 47.23 and a beta of 1.55. The business’s fifty day moving average is $536.56 and its 200-day moving average is $573.88.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same period last year, the firm posted $3.22 earnings per share. IDEXX Laboratories’s revenue was up 9.9% compared to the same quarter last year. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on IDXX shares. The Goldman Sachs Group initiated coverage on shares of IDEXX Laboratories in a research report on Friday, October 16th. They set a “buy” rating and a $740.00 price objective for the company. Leerink Partners decreased their target price on shares of IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. JPMorgan Chase & Co. dropped their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research report on Friday, October 16th. KeyCorp started coverage on shares of IDEXX Laboratories in a research report on Monday, October 12th. They issued a “sector weight” rating for the company. Finally, Citigroup upped their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $721.67.

Key Headlines Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates. IDEXX reported adjusted earnings of approximately $3.96–$3.98 per share versus the $3.71 consensus estimate. Revenue rose about 10% year over year to $1.21 billion, exceeding expectations of roughly $1.19 billion. IDEXX Laboratories Q3 earnings report
• Positive Sentiment: Recurring diagnostics remained the key growth engine. Recurring diagnostic revenue to veterinarians increased about 11%, demonstrating continued demand for IDEXX’s testing platforms and supporting the company’s earnings growth despite softer veterinary visit trends. IDEXX raises forecast
• Positive Sentiment: Management raised its full-year 2026 earnings and revenue guidance. The revised outlook suggests that IDEXX expects diagnostics growth, operating performance and customer adoption of its offerings to offset weakness in veterinary visit volumes. The guidance increase was the primary catalyst behind the strong stock reaction. IDEXX revises 2026 earnings guidance
• Neutral Sentiment: The earnings call reinforced a favorable long-term growth narrative. Management highlighted continued expansion in diagnostics, recurring revenue and productivity initiatives, which may support durable growth but also leaves the stock reliant on sustained premium valuation expectations. IDEXX Laboratories earnings call highlights
• Negative Sentiment: Margin trends and veterinary demand remain risks. Some reports noted that the higher profit forecast was not driven by stronger testing demand, while the margin outlook softened. Weak veterinary visits could pressure near-term volume growth if diagnostics expansion does not continue. IDEXX sales and margin outlook

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.